Abstracts tagged "giant cell arteritis"

Abstract Number: 2161 • 2015 ACR/ARHP Annual Meeting
Ustekinumab for the Treatment of Refractory Giant Cell Arteritis
Richard Conway^1,2, Lorraine O'Neill^3,4, Eileen O'Flynn³, Geraldine M. McCarthy^5,6, Conor Murphy⁷, Douglas J. Veale⁸, Ursula Fearon⁹ and Eamonn S. Molloy¹⁰, ¹CARD Newman Research Fellow, University College Dublin, Dublin, Ireland, ²Centre for Arthritis and Rheumatic Diseases, Dublin Academic Medical Centre, University College Dublin, Dublin, Ireland, ³Rheumatology, Dublin Academic Medical Centre, St. Vincent's University Hospital, Dublin, Ireland, ⁴Rheumatology, St. Vincent's University Hospital, Dublin 4, Ireland, ⁵Rheumatology, Mater Misericordiae University Hospital, Dublin 7, Ireland, ⁶University College Dublin, Dublin, Ireland, ⁷Department of Ophthalmology, Royal Victoria Eye and Ear Hospital, Dublin, Ireland, ⁸St Vincent's University Hospital, Centre for Arthritis and Rheumatic Diseases, Dublin Academic Medical Centre, Dublin 4, Ireland, ⁹St. Vincent's University Hospital, Centre for Arthritis and Rheumatic Diseases, Dublin Academic Medical Centre, Dublin 4, Ireland, ¹⁰St Vincent's University Hospital, Centre for Arthritis and Rheumatic Diseases, Dublin Academic Medical Centre, St Vincent's University Hospital, Dublin 4, Dublin 4, Ireland
Background/Purpose: Giant cell arteritis (GCA) requires treatment with high dose corticosteroids. Many patients require chronic steroid therapy with associated significant side effects. There is a…
Abstract Number: 1958 • 2015 ACR/ARHP Annual Meeting
Diagnostic Value of Ultrasonography-Derived Signs in Giant Cell Arteritis: Literature Review and Meta-Analysis
Fanny BUSQUET¹, Léa Rouxel², Thomas Barnetche³ and Thierry Schaeverbeke⁴, ¹intern of hospital, BORDEAUX, France, ²intern of hospital, Bordeaux, France, ³PHD, bordeaux, France, ⁴department head, Bordeaux, France
Background/Purpose: Giant Cell Arteritis (GCA) is the most common form of systemic inflammatory vasculitis in elderly people, with prevalence still increasing, and for which there…
Abstract Number: 1960 • 2015 ACR/ARHP Annual Meeting
a Structured and Extensive Training Program on Vascular Ultrasound, Results in an Excellent Agreement Between Ultrasound and Temporal Artery Biopsy in the Diagnosis of Giant Cell Arteritis
Stavros Chrysidis¹, Ulrich Fredberg², Uffe Møller Døhn³, Tove Lorenzen⁴, Lene Terslev⁵, Knud Larsen⁶ and Andreas P Diamantopoulos⁷, ¹Department of Rheumatology, Hospital of Southwest Denmark, Esbjerg, Denmark, ²Department of Internal Medicine, Diagnostic Centre Region Hospital Silkeborg Denmark, Silkeborg, Denmark, ³Center for Rheumatology and Spine Diseases, Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Rigshospitalet - Glostrup, University of Copenhagen, Glostrup, Denmark, ⁴Diagnostic Centre, Region Hospital Silkeborg, Silkeborg, Denmark, ⁵Copenhagen University Hospital at Glostrup, Copenhagen, Denmark, ⁶otolaryngology, Southwest hospital, Esbjerg, Denmark, ⁷Rheumatology, Haugesund Hospital for Rheumatic Diseases, Haugesund, Norway
Background/Purpose: There is an increased use of vascular ultrasound (US) for diagnosing giant cell arteritis (GCA). Consequently, extensive and structured training of ultrasonographers performing vascular…
Abstract Number: 1962 • 2015 ACR/ARHP Annual Meeting
Inter-Rater Analysis of Ultrasound and Histological Findings in Patients with Suspected Giant Cell Arteritis
Raashid Luqmani¹, Ellen Lee², Surjeet Singh³, Michael Gillett², Wolfgang A. Schmidt⁴, Mike Bradburn², Bhaskar Dasgupta⁵, Andreas P Diamantopoulos⁶, Wulf Forrester-Barker⁷, William Hamilton⁸, Shauna Masters⁹, Brendan McDonald¹⁰, Eugene McNally⁷, Colin T. Pease¹¹, Jennifer Piper⁷, John Salmon¹², Allan Wailoo², Konrad Wolfe¹³, Andrew Hutchings¹⁴ and TABUL Sonographers Group and TABUL Pathologists Group, ¹Nuffield Department of Orthopaedics Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, ²School of Health and Related Research, University of Sheffield, Sheffield, United Kingdom, ³1Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, ⁴Medical Center for Rheumatology and Clinical Immunology Berlin-Buch, Immanuel Krankenhaus Berlin, Berlin, Germany, ⁵Rheumatology, Southend University Hospital, Essex, United Kingdom, ⁶Department of Rheumatology, Hospital of Southern Norway Trust, Kristiansand, Norway, ⁷Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, ⁸Primary Care, University of Exeter, Exeter, United Kingdom, ⁹Nuffield Department of Orthopaedics Rheumatology and Musculoskeletal Science, University of Oxford, Oxford, United Kingdom, ¹⁰Department of Neuropathology and Ocular Pathology, Oxford University Hospitals NHS Trust, Oxford, United Kingdom, ¹¹Rheumatology, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, ¹²Ophthalmology, Oxford University Hospitals NHS Trust, Oxford, United Kingdom, ¹³Department of Pathology, Southend University Hospital, Essex, United Kingdom, ¹⁴Health Services Research Unit, London School of Hygiene and Tropical Medicine, London, United Kingdom
Background/Purpose: Ultrasound is emerging as an alternative test to performing a temporal artery biopsy in the diagnosis of giant cell arteritis (GCA). Little is known…
Abstract Number: 1965 • 2015 ACR/ARHP Annual Meeting
T Cell Activation, Proliferation and Differentiation Markers Lack Diagnostic Accuracy for Detecting Active GCA and PMR
Kornelis S.M. van der Geest¹, Wayel H. Abdulahad², Qi Wang², Mirjam Roffel², Gerda Horst², Abraham Rutgers², Annemieke M.H. Boots² and Elisabeth Brouwer², ¹Dept. of Rheumatology and Clinical Immunology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands, ²Rheumatology and Clinical Immunology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands
Background/Purpose: The most important biomarker in GCA and PMR patients is increased erythrocytes sedimentation rate (ESR) and/ or increased serum level of C-reactive protein (CRP).…
Abstract Number: 1966 • 2015 ACR/ARHP Annual Meeting
Active PMR and GCA Is Associated with Changes in Monocyte Subset Composition
Qi Wang¹, Kornelis S.M. van der Geest², Wayel H. Abdulahad¹, Johanna Westra³, Annemieke M.H. Boots¹ and Elisabeth Brouwer¹, ¹Rheumatology and Clinical Immunology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands, ²Hanzeplein 1, Hpc: Aa21, University Medical Center Groningen, University of Groningen, Groningen, Netherlands, ³Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands
Background/Purpose: Giant cell arteritis (GCA) and polymyalgia rheumatica (PMR) are two closely related syndromes affecting older people. Proinflammatory cytokine IL-6 is found increased in both…
Abstract Number: 1969 • 2015 ACR/ARHP Annual Meeting
Can We Predict the Relapse of Giant Cell Arteritis?
Alojzija Hocevar, Rok Ješe, Ziga Rotar, Sonja Praprotnik, Matija Tomšič and Saša Čučnik, Department of Rheumatology, University Medical Centre Ljubljana, Ljubljana, Slovenia
Background/Purpose: Relapses during glucocorticoid (GC) tapering are frequent in giant cell arteritis (GCA). Anemia at the time of GCA diagnosis was a predictor of flare…
Abstract Number: 1970 • 2015 ACR/ARHP Annual Meeting
Incidence and Predictors of Thoracic Aortic Damage in Biopsy-Proven Giant Cell Arteritis: A Single-Institution Cohort Study
Matthew J. Koster¹, Cristian Labarca², Cynthia S. Crowson³, Eric L. Matteson¹ and Kenneth J. Warrington¹, ¹Rheumatology, Mayo Clinic, Rochester, MN, ²Rheumatology, Clinica Alemana Universidad del Desarrollo, Santiago, Chile, ³Health Sciences Research, Mayo Clinic, Rochester, MN
Background/Purpose: Patients with giant cell arteritis (GCA) are at an increased risk for aortic structural damage; however, the timing and predisposing characteristics for development of…
Abstract Number: 880 • 2014 ACR/ARHP Annual Meeting
An Immunochip Study Confirms a Strong Contribution of HLA Class I and II Genes in the Susceptibility to Giant Cell Arteritis
Francisco David Carmona¹, Sarah Mackie², Jose Ezequiel Martin¹, John Taylor², Augusto Vaglio³, Lara Bossini-Castillo¹, Santos Castañeda⁴, Maria C. Cid⁵, José Hernández-Rodríguez⁶, Roser Solans⁷, Ricardo Blanco⁸, Lorenzo Beretta⁹, Claudio Lunardi¹⁰, Marco A. Cimmino¹¹, Cisca Wijmenga¹², Torsten Witte¹³, Julia Holle¹⁴, Frank Moosig¹⁴, Verena Schönau¹⁵, Andre Franke¹⁶, Øyvind Palm¹⁷, Andreas P. Diamantopoulos¹⁸, Benedicte A. Lie¹⁹, Simon Carette²⁰, David Cuthbertson²¹, Gary S. Hoffman²², Nader A. Khalidi²³, Curry L. Koening²⁴, Carol A. Langford²⁵, Carol McAlear²⁶, Larry Moreland²⁷, Paul A. Monach²⁸, Christian Pagnoux²⁰, Philip Seo²⁹, Antoine G. Sreih³⁰, Kenneth J. Warrington³¹, Steven R. Ytterberg³¹, Colin T. Pease³², Andrew Gough³³, Michael Green³⁴, Lesley Hordon³⁵, Stephen Jarrett³⁶, Richard Watts³⁷, Sarah Levy³⁸, Yusuf Patel³⁹, Sanjeet Kamath⁴⁰, Bhaskar Dasgupta⁴¹, Paul IW. de Bakker⁴², Bobby P.C. Koeleman⁴², Jennifer H. Barrett², Carlo Salvarani⁴³, Peter A. Merkel⁴⁴, Miguel A. Gonzalez-Gay⁸, Ann W. Morgan² and Javier Martin¹, ¹Immunology, Instituto de Parasitología y Biomedicina López-Neyra, IPBLN-CSIC, Armilla (Granada), Spain, ²NIHR-Leeds Musculoskeletal Biomedical Research Unit, University of Leeds, Leeds, United Kingdom, ³Unit of Nephrology, University Hospital of Parma, Parma, Italy, ⁴Rheumatology, Hospital Universitario de La Princesa, IISP, Madrid, Spain, ⁵Vasculitis Research Unit, Department of Autoimmune Diseases, Hospital Clínic University of Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), 08036- Barcelona, Spain, ⁶Vasculitis Research Unit, Department of Autoimmune Diseases, Hospital Clínic University of Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain, ⁷Autoimmune Systemic Diseases Unit, Department of Internal Medicine, Hospital Vall d'Hebron, Autonomous University of Barcelona, Barcelona, Spain, ⁸Department of Rheumatology, Hospital Universitario Marqués de Valdecilla, IFIMAV, Santander, Spain, ⁹Referral Center for Systemic Autoimmune Diseases, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico di Milano, Milan, Italy, ¹⁰Department of Medicine, Università degli Studi di Verona, Verona, Italy, ¹¹Department of Internal Medicine, Academic Unit of Clinical Rheumatology, University of Genova, Genova, Italy, ¹²Department of Genetics, University Medical Hospital Groningen, University of Groningen, Groningen, Netherlands, ¹³Clinic for Immunology and Rheumatology, Hannover Medical School, Hannover, Germany, ¹⁴Vasculitis Clinic, Klinikum Bad Bramstedt & University Hospital of Schleswig Holstein, Bad Bramstedt, Germany, ¹⁵Department of Rheumatology and Immunology, Universitätsklinikum Erlangen, Erlangen, Germany, ¹⁶Institute of Clinical Molecular Biology, Christian-Albrechts-University of Kiel, Kiel, Germany, ¹⁷Department of Rheumatology, Oslo University Hospital and University of Oslo, Oslo, Norway, ¹⁸Department of Rheumatology, Hospital of Southern Norway Trust, Kristiansand, Norway, ¹⁹Department of Medical Genetics, University of Oslo and Oslo University Hospital, Oslo, Norway, ²⁰Division of Rheumatology, University of Toronto, Toronto, ON, Canada, ²¹Department of Biostatistics, University of South Florida, Tampa, FL, ²²Center for Vasculitis Care and Research, Cleveland Clinic Foundation, Cleveland, OH, ²³Division of Rheumatology, St. Joseph’s Hospital, McMaster University, Hamilton, ON, Canada, ²⁴Division of Rheumatology, University of Utah, Salt Lake City, UT, ²⁵Center for Vasculitis Care and Research, Cleveland Clinic, Cleveland, OH, ²⁶Division of Rheumatology, Vasculitis Center, University of Pennsylvania, Philadelphia, PA, ²⁷Rheumatology & Clinical Immunology, Vasculitis Center, of University of Pittsburgh Medical Center, Pittsburgh, PA, ²⁸Section of Rheumatology, Vasculitis Center, Boston University School of Medicine, Boston, MA, ²⁹Rheumatology Division, Johns Hopkins Vasculitis Center, Johns Hopkins University, Baltimore, MD, ³⁰Medicine/Division of Rheumatology, The University of Pennsylvania, Philadelphia, PA, ³¹Division of Rheumatology, Mayo Clinic, Rochester, MN, ³²Department of Rheumatology, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, ³³Department of Rheumatology, Harrogate and District Foundation Trust, Harrogate, United Kingdom, ³⁴Department of Rheumatology, York Teaching Hospital NHS Foundation Trust, York, United Kingdom, ³⁵Department of Rheumatology, Mid Yorkshire Hospitals NHS Trust, Dewsbury, United Kingdom, ³⁶Department of Rheumatology, Mid Yorkshire Hospitals NHS Trust, Wakefield, United Kingdom, ³⁷Department of Rheumatology, Ipswich Hospital NHS Trust, Ipswich, United Kingdom, ³⁸Department of Rheumatology, Croydon Health Service NHS Trust, Croydon, United Kingdom, ³⁹Department of Rheumatology, Hull and East Yorkshire NHS Trust, Hull East Yorkshire, United Kingdom, ⁴⁰Department of Rheumatology, Staffordshire and Stoke-on-Trent Partnership NHS Trust, Staffordshire, United Kingdom, ⁴¹Department of Rheumatology, Southend University Hospital, Essex, United Kingdom, ⁴²Department of Medical Genetics, University Medical Center Utrecht, Utrecht, Netherlands, ⁴³Rheumatology Unit, Department of Internal Medicine, Azienda Ospedaliera ASMN, Istituto di Ricovero e Cura a Carattere Scientifico, Reggio Emilia, Italy, ⁴⁴University of Pennsylvania, Philadelphia, PA
Background/Purpose: Giant cell arteritis (GCA) is a chronic autoimmune vasculitis with an important genetic component. We aimed to identify relevant risk loci for GCA predisposition…
Abstract Number: 779 • 2014 ACR/ARHP Annual Meeting
Toll-like Receptor 2 Agonism Induces Inflammation, Angiogenesis and Cell Migration in Giant Cell Arteritis
Lorraine O'Neill¹, Aoife Maher¹, Jennifer McCormick², Conor Murphy³, Geraldine M. McCarthy⁴, Douglas J. Veale⁵, Ursula Fearon² and Eamonn S. Molloy¹, ¹Rheumatology, St. Vincent's University Hospital, Dublin 4, Ireland, ²Dublin Academic Medical Centre, Translational Rheumatology Research Group, Dublin, Ireland, ³Department of Ophthalmology, Royal Victoria Eye and Ear Hospital, Dublin, Ireland, ⁴Medicine/Rheumatology, Mater Misericordiae University Hospital, Dublin 7, Ireland, ⁵Translational Rheumatology Research Group, St. Vincent's University Hospital, Dublin 4, Ireland
Background/Purpose Activation of dendritic cells (DCs) is one of the earliest inciting events in Giant Cell Arteritis (GCA). TLR 2 is expressed on DCs in…
Abstract Number: 882 • 2014 ACR/ARHP Annual Meeting
A Signature of microRNAs Overexpressed in Inflamed Temporal Arteries of Patients with Giant Cell Arteritis
Stefania Croci¹, Alessandro Zerbini¹, Luigi Boiardi², Francesco Muratore², Alessandra Bisagni³, Giulia Pazzola², Luca Cimino⁴, Antonio Moramarco⁴, Davide Nicoli⁵, Enrico Farnetti⁶, Bruno Casali⁶, Alberto Cavazza³, Maria Parmeggiani⁷ and Carlo Salvarani², ¹Clinical Immunology, Allergology and Advanced Biotechnologies Unit,, Arcispedale S Maria Nuova, Reggio Emilia, Italy, ²Rheumatology Unit, Arcispedale S Maria Nuova, Reggio Emilia, Italy, ³Pathology Unit, Arcispedale S Maria Nuova, Reggio Emilia, Italy, ⁴Ophthalmology Unit, Arcispedale S Maria Nuova, Reggio Emilia, Italy, ⁵Laboratory of Molecular Biology, Arcispedale S Maria Nuova, Reggio Emilia, Italy, ⁶Laboratory of Molecular Biology,, Arcispedale S Maria Nuova, Reggio Emilia, Italy, ⁷Clinical Immunology, Allergology and Advanced Biotechnologies Unit, Arcispedale S Maria Nuova, Reggio Emilia, Italy
Background/Purpose: MicroRNAs (miRNAs) are small, non-coding RNAs that suppress gene expression at post-transcriptional level. MiRNAs can regulate innate and adaptive immunity. Moreover, they have been…
Abstract Number: 777 • 2014 ACR/ARHP Annual Meeting
Influence of the IL17A Locus in Giant Cell Arteritis Susceptibility
Javier Martin¹, Ana Márquez², José Hernández-Rodríguez³, Maria C. Cid⁴, Roser Solans⁵, Santos Castañeda⁶, Inmaculada C. Morado⁷, Javier Narváez⁸, Victor M. Martinez-Taboada⁹, Norberto Ortego-Centeno¹⁰, Bernardo Sopeña¹¹, Jordi Monfort¹², Maria Jesus Garcia-Villanueva¹³, Luis Caminal-Montero¹⁴, Eugenio De Miguel¹⁵, Ricardo Blanco¹⁶, Øyvind Palm¹⁷, Øyvind Molberg¹⁸, Joerg Latus¹⁹, Niko Braun¹⁹, Frank Moosig²⁰, Torsten Witte²¹, Lorenzo Beretta²², Alessandro Santaniello²³, Giulia Pazzola²⁴, Luigi Boiardi²⁵, Carlo Salvarani²⁶ and Miguel A. Gonzalez-Gay⁹, ¹Immunology, Instituto de Parasitología y Biomedicina López-Neyra, IPBLN-CSIC, Armilla (Granada), Spain, ²Instituto de Parasitologia y Biomedicina López-Neyra (IPBLN-CSIC) and Systemic Autoimmune Diseases Unit, Hospital Clínico San Cecilio, Granada, Spain, ³Vasculitis Research Unit, Department of Autoimmune Diseases, Hospital Clínic University of Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain, ⁴Vasculitis Research Unit, Department of Autoimmune Diseases, Hospital Clínic University of Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), 08036- Barcelona, Spain, ⁵Autoimmune Systemic Diseases Unit, Department of Internal Medicine, Hospital Vall d'Hebron, Autonomous University of Barcelona, Barcelona, Spain, ⁶Department of Rheumatology, Hospital de la Princesa, IIS-Princesa, Madrid, Spain, ⁷Department of Rheumatology, Hospital Clínico San Carlos, Madrid, Spain, ⁸Rheumatology, Hospital Universitario de Bellvitge. Barcelona. Spain, Barcelona, Spain, ⁹Department of Rheumatology, Hospital Universitario Marqués de Valdecilla, IFIMAV, Santander, Spain, ¹⁰Systemic Autoimmune Diseases Unit, Hospital Clínico San Cecilio, Granada, Spain, ¹¹Department of Internal Medicine, Complejo Hospitalario Universitario de Vigo, Vigo, Spain, ¹²Department of Rheumatology, Grup de recerca cel•lular en inflamació i cartílag. IMIM (Institut de Recerca Hospital del Mar), Barcelona, Spain, ¹³Department of Rheumatology, Hospital Ramón y Cajal, Madrid, Spain, ¹⁴Department of Internal Medicine, Hospital Universitario Central de Asturias, Oviedo, Spain, ¹⁵Department of Rheumatology, Hospital Universitario La Paz, Madrid, Spain, ¹⁶Hospital Marques de Valdecilla, Santander, Spain, ¹⁷Department of Rheumatology, Oslo University Hospital and University of Oslo, Oslo, Norway, ¹⁸Department of Rheumatology, Oslo University Hospital Rikshospitalet, Oslo, Norway, ¹⁹Department of Internal Medicine, Division of Nephrology, Robert-Bosch-Hospital, Stuttgart, Germany, ²⁰Department of Clinical Immunology and Rheumatology, University of Luebeck, Bad Bramstedt, Germany, ²¹Clinic for Immunology and Rheumatology, Hannover Medical School, Hannover, Germany, ²²Referral Center for Systemic Autoimmune Diseases, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico di Milano, Milan, Italy, ²³Referral Center for Systemic Autoimmune Diseases, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano, Milan, Italy, ²⁴Rheumatology Unit, Arcispedale S Maria Nuova, Reggio Emilia, Italy, ²⁵Unita` Operativa di Reumatologia, Azienda Ospedaliera ASMN, Istituto di Ricovero e Cura a Carattere Scientifico, Reggio Emilia, Italy, ²⁶Rheumatology Unit, Department of Internal Medicine, Azienda Ospedaliera ASMN, Istituto di Ricovero e Cura a Carattere Scientifico, Reggio Emilia, Italy
Background/Purpose: A recent study has showed that the number of Th17 lymphocytes is significantly increased in patients with GCA, resulting in an imbalance between Th17…
Abstract Number: 808 • 2014 ACR/ARHP Annual Meeting
Biomarkers of Disease Activity in Vasculitis
Alicia Rodriguez-Pla¹, Roscoe L. Warner², David Cuthbertson³, Simon Carette⁴, Gary S. Hoffman⁵, Nader A. Khalidi⁶, Curry L Koening⁷, Carol A. Langford⁸, Kathleen Maksimowicz-McKinnon⁹, Larry W. Moreland¹⁰, Christian Pagnoux⁴, Philip Seo¹¹, Ulrich Specks^12,13, Kenneth J. Warrington¹⁴, Steven R. Ytterberg¹⁵, Peter A. Merkel¹⁶, Kent J. Johnson², Paul A. Monach¹⁷ and For the Vasculitis Research Consortium¹⁸, ¹Rheumatology, Boston University, Boston, MA, ²Pathology, University of Michigan, Ann Arbor, MI, ³Department of Biostatistics, University of South Florida, Tampa, FL, ⁴Division of Rheumatology, University of Toronto, Toronto, ON, Canada, ⁵Center for Vasculitis Care and Research, Cleveland Clinic Foundation, Cleveland, OH, ⁶Internal Medicine/Rheumatology, McMaster University, Hamilton, ON, Canada, ⁷Division of rheumatology, George E. Wahlen Department of Veterans Affairs Medical Center Salt Lake City and University of Utah, University of Utah School of Medicine, Salt Lake City, UT, ⁸Center for Vasculitis Care and Research, Cleveland Clinic, Cleveland, OH, ⁹Rheumatology, Henry Ford Hospital, Detroit, MI, ¹⁰Medicine, Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ¹¹Rheumatology Division, Johns Hopkins Vasculitis Center, Johns Hopkins University, Baltimore, MD, ¹²Frederichs Dr NW, Mayo Clinic, Rochester, MN, ¹³Mayo Clinic, Rochester, MN, ¹⁴Division of Rheumatology, Mayo Clinic, Rochester, MN, ¹⁵Rheumatology Division, Mayo Clinic, Rochester, MN, ¹⁶University of Pennsylvania, Philadelphia, PA, ¹⁷Section of Rheumatology, Vasculitis Center, Boston University School of Medicine, Boston, MA, ¹⁸U Pennsylvania, Philadelphia, PA
Background/Purpose To identify circulating proteins that distinguish between active vasculitis and remission in giant cell arteritis (GCA), Takayasu's arteritis (TAK), polyarteritis nodosa (PAN) and eosinophilic…
Abstract Number: 88 • 2014 ACR/ARHP Annual Meeting
Microbiomes of Inflammatory and Non-Inflammatory Thoracic Aortic Aneurysms
Pauline Funchain*^1,2,3, Gary S. Hoffman*⁴, Lars Svensson⁵, Eric Roselli⁵, Gosta Pettersson⁶, Douglas Johnston⁶, Edward Soltesz⁶, Ritu Chakravarti⁷, Alison Clifford⁸ and Charis Eng², ¹Genomic Medicine Institute, Lerner Research Institute, Cleveland, OH, ²Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, OH, ³Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH, ⁴Center for Vasculitis Care and Research, Cleveland Clinic, Cleveland, OH, ⁵Department of Thoracic and Cardiovascular Surgery, Cleveland Clinic Foundation, Cleveland, OH, ⁶Thoracic and Cardiovascular Surgery, Cleveland Clinic Foundation, Cleveland, OH, ⁷Lerner Research Institure, Cleveland Clinic, Cleveland, OH, ⁸Rheumatic and Immunologic Diseases, Cleveland Clinic Foundation, Cleveland, OH
Background/Purpose: Aortitis may occur in the context of multifocal large and medium-sized vessel diseases such as giant cell arteritis (GCA) or Takayasu arteritis (TAK) and…
Abstract Number: 801 • 2014 ACR/ARHP Annual Meeting
Venothromboembolism in Large Vessel Vasculitis
Sankalp V. Bhavsar¹, Nader A. Khalidi², Simon Carette³, David Cuthbertson⁴, Peter C. Grayson⁵, Gary S. Hoffman⁶, Curry L. Koening⁷, Carol A. Langford⁸, Carol McAlear⁹, Larry Moreland¹⁰, Paul A. Monach¹¹, Christian Pagnoux³, Philip Seo¹², Kenneth J. Warrington¹³, Steven R. Ytterberg¹³ and Peter A. Merkel¹⁴, ¹Division of Rheumatology, McMaster University, Hamilton, ON, Canada, ²Division of Rheumatology, St. Joseph’s Hospital, McMaster University, Hamilton, ON, Canada, ³Division of Rheumatology, University of Toronto, Toronto, ON, Canada, ⁴Department of Biostatistics, University of South Florida, Tampa, FL, ⁵NIAMS Systemic Autoimmunity Branch, National Institutes of Health, Bethesda, MD, ⁶Center for Vasculitis Care and Research, Cleveland Clinic Foundation, Cleveland, OH, ⁷Division of Rheumatology, University of Utah, Salt Lake City, UT, ⁸Center for Vasculitis Care and Research, Cleveland Clinic, Cleveland, OH, ⁹Division of Rheumatology, Vasculitis Center, University of Pennsylvania, Philadelphia, PA, ¹⁰Vasculitis Center, of University of Pittsburgh Medical Center, Pittsburgh, PA, ¹¹Section of Rheumatology, Vasculitis Center, Boston University School of Medicine, Boston, MA, ¹²Rheumatology Division, Johns Hopkins Vasculitis Center, Johns Hopkins University, Baltimore, MD, ¹³Division of Rheumatology, Mayo Clinic, Rochester, MN, ¹⁴University of Pennsylvania, Philadelphia, PA
Background/Purpose: Venous thromboembolic disease (VTE) is a recognized characteristic of various systemic vasculitides, particularly small-vessel vasculitis. However, there are no reports describing the frequency of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].